 | |
- close
- close
|
Business Wire
Nov 5
Comment
Maxygen, Inc. (Nasdaq: MAXY), a biotechnology company focused on the development of improved protein drugs, today announced financial results for the quarter ended September 30, 2009. Third Quarter 2009 Financial Results Maxygen reported a net loss
FierceBiotech
Sep 29
Comment
Just days after transferring $10 million in cash and all its work on protein pharmaceuticals to a new joint venture with Astellas Pharma, Maxygen (MAXY) has announced a restructuring that will see its CEO of 11 years leave the company...
Business Wire
Sep 28
Comment
Maxygen, Inc. (Nasdaq:MAXY) announced today that James Sulat, who currently serves as a director of the company, has been appointed to serve as Maxygen’s Chief Executive Officer, effective October 1, 2009. Mr. Sulat will replace Russell Howard, who
Business Wire
Sep 21
Comment
Maxygen, Inc. (Nasdaq:MAXY) today announced the consummation of the transactions contemplated by the previously announced joint venture agreement between Maxygen and Astellas Pharma Inc. Under the joint venture transaction, which closed on September
StreetInsider.com
Aug 6
Comment
Visit StreetInsider.com at http://www.streetinsider.com/Earnings/Maxygen+%28MAXY%29+Reports+Q2+Loss+of+%240.15%2C+Misses+by+4c/4853705.html for the full story.
|
Topic
Top news source/blog that we're missing
Why do you recommend this news source?
|
||
more ▼WIKI ANALYSIS
WIKI ANALYSIS
 |
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article. |
MAXY AT A GLANCE
References
| ||||||
|
|
